Key facts
- XDemics’s last known valuation is $33.5M (Feb 2026).
- It has raised $14.8M across 3 recorded rounds; the latest was Early Stage VC ($7.4M) in Oct 2025.
- XDemics has filed 4 Form Ds with the SEC, most recently Dec 2024 ($5.5M sold to 3 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for XDemics
Create free account
No card required
Funding rounds
3 roundsAbout XDemics
Operator of a biotechnology research firm in Novato, California. The company offers the production of cell and viral-based therapeutics for the treatment of human disease, enabling healthcare professionals to provide new treatment options for patients.
- Sector
- Healthcare
- HQ
- Novato, CA, United States
- Founded
- 2017
- Employees
- 9
- Website
- xdemics.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
XDemics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in XDemics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on XDemics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.